Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating reiterated by analysts at HC Wainwright in ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target reduced by stock analysts at Deutsche Bank ...

NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Wednesday’s 10 Top Performers. In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) ...

Regenxbio (NASDAQ:RGNX) and Solid Biosciences (NASDAQ:SLDB) witnessed contrasting fortunes on Tuesday after Sarepta ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at ...

12 analysts have shared their evaluations of Sarepta Therapeutics (NASDAQ:SRPT) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a ...

We recently published a list of 10 Firms Heavily Hit by Market Pessimism. In this article, we are going to take a look at ...

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 24.9% in the pre-market session after the company reported ...

Shares of Sarepta Therapeutics have struggled for the past year due to concerns about the commercial potential of its gene ...

HighTower Advisors LLC decreased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 6.5% during the ...

Cantor Fitzgerald reiterated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a ...